Enhanced Tumour Specificity of an Anti-carcinoembrionic Antigen Fab' Fragment by Poly(ethylene Glycol) (PEG) Modification

Overview

Journal Br J Cancer

Specialty Oncology

Date 1996 Jan 1

PMID 8546903

Citations 9

Authors

C Delgado

R B Pedley

A Herraez

R Boden

J A Boden

P A Keep

K A Chester

D Fisher

R H Begent

G E FRANCIS

Affiliations

Soon will be listed here.

Abstract

Polyethylene glycol (PEG) modification of a chimeric Fab' fragment (F9) of A5B7 (alpha-CEA), using an improved coupling method, increases its specificity for subcutaneous LS174T tumours. PEGylation increased the area under the concentration-time curve (AUC0-144) in all tissues but there were significant differences (variance ratio test, F = 27.95, P < 0.001) between the proportional increases in AUC0-144, with the tumour showing the greatest increase. The increase in AUCtumour from F9 to PEG-F9 was similar to the reported increase from Fab' to F(ab')2 while the increase in AUCblood by PEGylation of F9 was only 21% of the reported increase from Fab' to whole IgG. A two sample t-test showed no significant differences between maximal tumour/tissue ratios for PEG-F9 and F9 while the tumour/tissue ratios for PEG-F9 remained high over a longer period, with tumour levels at least double those for F9. PEG-F9 emerges as a new generation antibody with potential advantages for both radioimmunotherapy and tumour imaging. Since there was a reduction in antigen binding, optimisation of PEGylation might further improve tumour specificity. The latter resulted from complex effects on both the entry into and exit rates from tumour and normal tissues in a tissue-specific fashion.

Citing Articles

Research progress on the PEGylation of therapeutic proteins and peptides (TPPs).

Li C, Li T, Tian X, An W, Wang Z, Han B Front Pharmacol. 2024; 15:1353626.

PMID: 38523641 PMC: 10960368. DOI: 10.3389/fphar.2024.1353626.

High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation.

Mendler C, Friedrich L, Laitinen I, Schlapschy M, Schwaiger M, Wester H MAbs. 2014; 7(1):96-109.

PMID: 25484039 PMC: 4622060. DOI: 10.4161/19420862.2014.985522.

Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET.

Li L, Turatti F, Crow D, Bading J, Anderson A, Poku E J Nucl Med. 2010; 51(7):1139-46.

PMID: 20554731 PMC: 3247072. DOI: 10.2967/jnumed.109.074153.

Targeted strategies for henipavirus therapeutics.

Bossart K, Bingham J, Middleton D Open Virol J. 2009; 1:14-25.

PMID: 19440455 PMC: 2675550. DOI: 10.2174/1874357900701010014.

Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.

Thurber G, Schmidt M, Wittrup K Adv Drug Deliv Rev. 2008; 60(12):1421-34.

PMID: 18541331 PMC: 2820307. DOI: 10.1016/j.addr.2008.04.012.

References

Thomas G, Chappell M, Dykes P, Ramsden D, Godfrey K, Ellis J . Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: a biomathematical model. Cancer Res. 1989; 49(12):3290-6. View

Pedley R, Boden J, Boden R, Begent R, Turner A, HAINES A . The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br J Cancer. 1994; 70(6):1126-30. PMC: 2033704. DOI: 10.1038/bjc.1994.459. View

Delgado C, Patel J, FRANCIS G, Fisher D . Coupling of poly(ethylene glycol) to albumin under very mild conditions by activation with tresyl chloride: characterization of the conjugate by partitioning in aqueous two-phase systems. Biotechnol Appl Biochem. 1990; 12(2):119-28. View

Buchegger F, Pelegrin A, DELALOYE B, Bischof-Delaloye A, Mach J . Iodine-131-labeled MAb F(ab')2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J Nucl Med. 1990; 31(6):1035-44. View

Kitamura K, Takahashi T, Takashina K, Yamaguchi T, Noguchi A, Tsurumi H . Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization. Biochem Biophys Res Commun. 1990; 171(3):1387-94. DOI: 10.1016/0006-291x(90)90839-f. View

Delgado C, Anderson R, FRANCIS G, Fisher D . Separation of cell mixtures by immunoaffinity cell partitioning: strategies for low abundance cells. Anal Biochem. 1991; 192(2):322-8. DOI: 10.1016/0003-2697(91)90543-3. View

Kitamura K, Takahashi T, Yamaguchi T, Noguchi A, Takashina K, Tsurumi H . Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. Cancer Res. 1991; 51(16):4310-5. View

Yoshioka H . Surface modification of haemoglobin-containing liposomes with polyethylene glycol prevents liposome aggregation in blood plasma. Biomaterials. 1991; 12(9):861-4. DOI: 10.1016/0142-9612(91)90075-l. View

Yorke E, Beaumier P, Wessels B, Fritzberg A, Morgan Jr A . Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: a predictive model based on mouse pharmacokinetics. Int J Rad Appl Instrum B. 1991; 18(8):827-35. DOI: 10.1016/0883-2897(91)90090-8. View

10.

Delgado C, Sancho P, Mendieta J, Luque J . Ligand-receptor interactions in affinity cell partitioning. Studies with transferrin covalently linked to monomethoxypoly(ethylene glycol) and rat reticulocytes. J Chromatogr. 1992; 594(1-2):97-103. DOI: 10.1016/0021-9673(92)80316-m. View

11.

Malik F, Delgado C, Knusli C, Irvine A, Fisher D, FRANCIS G . Polyethylene glycol (PEG)-modified granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved biological activity. Exp Hematol. 1992; 20(8):1028-35. View

12.

Knusli C, Delgado C, Malik F, Domine M, Tejedor M, Irvine A . Polyethylene glycol (PEG) modification of granulocyte-macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity. Br J Haematol. 1992; 82(4):654-63. DOI: 10.1111/j.1365-2141.1992.tb06940.x. View

13.

Pedley R, Boden J, Boden R, Dale R, Begent R . Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model. Br J Cancer. 1993; 68(1):69-73. PMC: 1968289. DOI: 10.1038/bjc.1993.288. View

14.

Yuan J . Estimation of variance for AUC in animal studies. J Pharm Sci. 1993; 82(7):761-3. DOI: 10.1002/jps.2600820718. View

15.

Chester K, Robson L, Keep P, Pedley R, Boden J, Boxer G . Production and tumour-binding characterization of a chimeric anti-CEA Fab expressed in Escherichia coli. Int J Cancer. 1994; 57(1):67-72. DOI: 10.1002/ijc.2910570113. View

16.

Lane D, Eagle K, Begent R, Green A, Casey J, Keep P . Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies. Br J Cancer. 1994; 70(3):521-5. PMC: 2033373. DOI: 10.1038/bjc.1994.338. View

17.

Tozer G, Shaffi K, Prise V, Cunningham V . Characterisation of tumour blood flow using a 'tissue-isolated' preparation. Br J Cancer. 1994; 70(6):1040-6. PMC: 2033701. DOI: 10.1038/bjc.1994.445. View

18.

Fujimori K, Covell D, Fletcher J, Weinstein J . Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res. 1989; 49(20):5656-63. View